Program Book and Abstracts - ISCD

180 — VERTEBRAL FRACTURE RISK IS REDUCED FOR WOMEN WHO LOSE FEMORAL NECK BONE MINERAL DENSITY
DURING TERIPARATIDE TREATMENT
Nelson B. Watts, Director, University of Cincinnati Bone Health and Osteoporosis Center, Paul D. Miller, Colorado Center for Bone
Research, Robert Marcus, MD, Eli Lilly & Company, Peiqi Chen, PhD, Eli Lilly & Company, Jody Arsenault, PhD (Eli Lilly) Kelly Krohn, MD
(Eli Lilly)
Measuring bone mineral density (BMD) is a commonly-accepted way of monitoring response to therapy, and loss of BMD is sometimes viewed as a
therapeutic failure. In the Fracture Prevention Trial (FPT) most women treated with teriparatide (TPTD) showed a gain in lumber spine BMD at 1yr.
However, some women had no gain or loss in hip BMD at 1yr (Gallagher et al., 2006). The objective of this analysis was to test the hypothesis that
women who received TPTD and lost femoral neck (FN) BMD at 1yr would, nevertheless, benefit from treatment, compared with placebo (PL).
Using data from the FPT, we compared risk reductions of new vertebral fractures with various ranges of change in FN BMD at 1yr. At baseline
women were randomized to PL, TPTD 20 or 40¼g/day by injection. FN BMD was measured at baseline and 12 months. New vertebral fractures
were assessed by lateral spine radiographs at baseline and study endpoint. Significantly fewer women lost more than 4% FN BMD at 1yr in the
TPTD group (82/816=10%) compared to PL (61/400=15%). Women treated with TPTD who lost more than 4% FN BMD at 1yr had a vertebral
fracture risk reduction of 89% [RR 0.11(95 CI, 0.03 to 0.45)] compared to PL. Vertebral fracture risk reduction relative to PL was consistent across
a range of change in FN BMD at 1yr (interaction p value=0.40). Women who received TPTD and lost FN BMD at 1yr still benefit from a substantial
reduction in risk of vertebral fracture compared to placebo.
171 — COMPARISON OF VITAMIN D SUPPLEMENTATION REGIMENS
Dessa Gemar, University of Wisconsin Osteoporosis Clinical Research Program, Abbey Woods, University of Wisconsin Osteoporosis
Clinical Research Program, Jean Engelke, University of Wisconsin Osteoporosis Clinical Research Program, Diane Krueger, University of
Wisconsin Osteoporosis Clinical Research Program, Neil Binkley University of Wisconsin Osteoporosis Clinical Research Program
Ergocalciferol (D2) is assumed to be less effective than cholecalciferol (D3) in maintaining serum 25-hydroxyvitamin D [25(OH)D], however, data
supporting this are limited. Additionally, daily treatment adherence is often poor, prompting clinicians to prescribe once-monthly high-dose D. When
dosing monthly, it is logical that trough 25(OH)D measurement is appropriate, however this has not been investigated. As such, the purpose of this
year-long randomized, double-blind trial was to evaluate the effect of daily (1,600 IU) versus once-monthly (50,000 IU) D2 or D3 dosing on serum
25(OH)D in adults age 65+. Utility of obtaining trough 25(OH)D measurements and effect of weight and baseline 25(OH)D on response was
investigated. Preliminary data from 32 participants through six months are reported. Baseline mean age was 77 years and mean 25(OH)D was 25.2
± 3.3 ng/ml; 34% were